AmSurg (Nasdaq: AMSG ) is expected to report Q4 earnings on Feb. 25. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AmSurg's revenues will increase 6.5% and EPS will grow 8.7%.
The average estimate for revenue is $237.9 million. On the bottom line, the average EPS estimate is $0.50.
Last quarter, AmSurg reported revenue of $226.4 million. GAAP reported sales were 16% higher than the prior-year quarter's $194.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.49. GAAP EPS of $0.49 for Q3 were 17% higher than the prior-year quarter's $0.42 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 53.9%, 220 basis points worse than the prior-year quarter. Operating margin was 29.7%, 160 basis points worse than the prior-year quarter. Net margin was 6.8%, 10 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $926.1 million. The average EPS estimate is $2.01.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 138 members out of 146 rating the stock outperform, and eight members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 50 give AmSurg a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AmSurg is hold, with an average price target of $29.17.
Is AmSurg the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.